← Leaderboards
Melanie R Palomares
University Of Southern California
$3,261,023
Attributed
$3,261,023
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $709.3K · FY2006–13$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$3,261,023 · 10
By mechanism
R01$2,510,236 · 1
M01$750,787 · 9
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Simon Andrew Gayther$9,015,265
- Jeffrey N Weitzel$10,932,306
- Leslie Bernstein$25,541,709
- Smita Bhatia$27,398,641
- Keiko Kurita$39,852
Others in their field
Top investigators on “Institution”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,187,810,557
- Leonard Freedman · Leidos Biomedical Research, Inc.$835,530,754
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$566,554,288
- Bambra Strokes · Ppd Development Lp$526,656,217
Research focus
InstitutionWomanResearch PersonnelUnited States National Institutes Of HealthGrantSafetyDoseSourceComputer Retrieval Of Information On Scientific Projects DatabaseSymptomsBone MetabolismMalignant NeoplasmsFundingResourcesFemaleMalignant Breast NeoplasmCancer TherapyS LymphomaBreast Cancer PreventionBenignCharacteristicsBreastBreast DiseasesBlood
Grant awards (13)
Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction$571,394
R01 · FY2013 · CA · contact PI
Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction$628,869
R01 · FY2012 · CA · contact PI
Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction$600,681
R01 · FY2011 · CA · contact PI
Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction$709,292
R01 · FY2010 · CA · contact PI
BLOOD TUMOR MARKERS FOR MOLECULAR DIAGNOSIS OF BREAST DISEASE AND MONITORING$228,419
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE I PREVENTION TRIAL OF ACTIVIN TM GRAPE SEED EXTRACT AS AN$27,828
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: A TRANSLATIONAL BREAST CANCER PREVENTION TRIAL MUSHROOM POWDER I$22,029
M01 · FY2009 · RR · contact PI
BLOOD TUMOR MARKERS FOR MOLECULAR DIAGNOSIS OF BREAST DISEASE AND MONITORING$109,357
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE I PREVENTION TRIAL OF ACTIVIN TM GRAPE SEED EXTRACT AS AN$98,541
M01 · FY2008 · RR · contact PI
BLOOD TUMOR MARKERS FOR MOLECULAR DIAGNOSIS OF BREAST DISEASE AND MONITORING$151,182
M01 · FY2007 · RR · contact PI
PHASE I PREVENTION TRIAL OF ACTIVIN TM GRAPE SEED EXTRACT AS AN AROMATASE INHIBI$60,086
M01 · FY2007 · RR · contact PI
PHASE I PREVENTION TRIAL OF ACTIVIN TM GRAPE SEED EXTRACT AS AN AROMATASE$52,257
M01 · FY2006 · RR · contact PI
BLOOD TUMOR MARKERS FOR MOLECULAR DIAGNOSIS OF BREAST DISEASE AND MONITORING$1,088
M01 · FY2006 · RR · contact PI